Clinical Investigation of the VytronUS Ablation System for Treatment of Symptomatic Drug-refractory Paroxysmal Atrial Fibrillation

Inclusion Criteria: * Age between 18 and 75 years * History of symptomatic recurrent paroxysmal atrial fibrillation (PAF) in the prior year, defined by: 1. Two or more symptomatic AF episodes lasting greater than 30 seconds duration that self-terminate and lasting no more than 7 continuous days. An episode of AF ≤ 48 hours duration terminated with electrical or pharmacologic cardioversion counts as a paroxysmal atrial fibrillation episode. 2. At least one episode of paroxysmal atrial fibrillation (PAF) documented on 12-lead ECG, event monitor, or telemetry monitor in the prior year * Paroxysmal atrial fibrillation refractory to at least one Beta Blocker, Calcium Channel Blocker, or Class I or Class III anti-arrhythmic drug (AAD). * Subject is indicated for a pulmonary vein ablation according to society guidelines or investigational site practice. * Subject is able and willing to give informed consent. * Willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full duration of the study Exclusion Criteria: * Prior LA ablation or surgery * Persistent, longstanding persistent, or permanent AF * AF secondary to electrolyte imbalance, thyroid disease or reversible or non-cardiac cause * NYHA Class III or IV congestive heart failure * Rheumatic heart disease * Atrial myxoma * LVEF \<40% measured by acceptable cardiac testing (e.g. TTE, TEE) * Anteroposterior LA diameter \>5.5cm or \<3.5cm by TTE, CT or MRI * Presence of intracardiac thrombus (including a known history of thrombus) within 30 days prior to the index ablation procedure * Presence of pulmonary vein stent(s) * Presence of pre-existing pulmonary narrowing or pulmonary vein stenosis greater than 70% * Presence of pre-existing pericardial effusion